Physician profile
Christopher Michael Allen
NPI 1366530727
$2,607.51
in general payments reported to CMS, 2019-2025
15 companies · $226 in 2025
The $226 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $94.21 · 2021: $494 · 2022: $333 · 2023: $507 · 2024: $375 · 2025: $226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $624.48 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $493.00 | 2021-2025 | Total30, Precision7 |
| Bausch & Lomb Americas INC. | $220.45 | 2022-2024 | Infuse |
| Glaukos Corporation | $216.36 | 2020-2024 | Ce-Marked Kxla System |
| Optovue, INC. | $144.22 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $132.98 | 2023 | Acuvue |
| Amgen INC. | $125.00 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $114.48 | 2019 | |
| Aerie Pharmaceuticals, INC. | $113.27 | 2019 | |
| Shire North American Group INC | $103.05 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.54 | 2019 | |
| Visionix USA, INC | $90.91 | 2022 | |
| Allergan, INC. | $67.78 | 2021 | |
| Oyster Point Pharma, INC. | $50.00 | 2022 | |
| Abb Con-Cise Optical Group LLC | $13.99 | 2025 | Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.